Is Protalix Biotherapeutics, Inc. PLX stock Halal to invest in?

Yes, as of September 2026, Protalix Biotherapeutics, Inc. stock (PLX) is classified as a Shariah compliant stock. The verdict comes from AAOIFI Shariah Standard No. 21, the benchmark most Islamic scholars and institutions use to screen Halal stocks. Protalix Biotherapeutics, Inc. clears each of the four screens this month: its non-permissible income stays inside the 5% ceiling, both interest-bearing debt and interest-bearing investments stay inside the 30% caps, and there are no impermissible preference shares. The stock's current purification factor is 99.45%. Compliance is reassessed every month as updated screening data arrives, and a stock's status can change when new financial reports are released. You can always check the current status of Protalix Biotherapeutics, Inc. and explore other Shariah compliant stocks in the Tabadulat app.

How often is Protalix Biotherapeutics, Inc. PLX reviewed for Shariah compliance?

Tabadulat reviews Protalix Biotherapeutics, Inc. PLX for Shariah compliance every month. Each review applies the AAOIFI Shariah Standard No. 21 methodology, screening the company's business activities, non-permissible income, interest-bearing investments, interest-bearing debt, and preference shares, against the company's latest available financial data. The process operates under the direct supervision of Tabadulat's dedicated Shariah Supervisory Board of Islamic finance scholars. Because compliance depends on financial ratios that move with market capitalisation and reported results, a stock's status can change from one review to the next. Monthly screening ensures the status shown for Protalix Biotherapeutics, Inc. reflects current financial data rather than an outdated assessment, and Tabadulat app users are notified if a holding in their portfolio becomes non-compliant.

Does Protalix Biotherapeutics, Inc. PLX pass the AAOIFI Non Permissible Income criteria?

Yes, as of September 2026, Protalix Biotherapeutics, Inc. stock (PLX) passes the AAOIFI non-permissible income screen. Each month Tabadulat measures Protalix Biotherapeutics, Inc.'s income from impermissible sources, covering Riba, conventional financial services, alcohol, gambling and tobacco, against AAOIFI's 5% revenue ceiling. The latest screening puts the company inside the limit. Even permissible levels of incidental impure income should still be purified: investors donate the corresponding share of dividends to charity, as reflected in the stock's purification factor. This screen is reassessed monthly using the company's latest financial disclosures.

Does Protalix Biotherapeutics, Inc. PLX pass the AAOIFI Interest Bearing Investments criteria?

Yes, as of September 2026, Protalix Biotherapeutics, Inc. stock (PLX) passes the AAOIFI interest-bearing investments screen. Under AAOIFI Shariah Standard No. 21, the cash a company places in interest-earning instruments (such as conventional deposits, bonds, treasury bills and money-market funds) must remain below 30% of its market capitalisation. This limit ensures shareholders are not materially profiting from Riba (interest). Protalix Biotherapeutics, Inc.'s interest-bearing investments are currently within the 30% threshold. Because the ratio is measured against market capitalisation, it can move with the share price as well as the balance sheet, which is why Tabadulat rescreens the stock every month.

Does Protalix Biotherapeutics, Inc. PLX pass the AAOIFI Interest Bearing Debt criteria?

Yes, as of September 2026, Protalix Biotherapeutics, Inc. stock (PLX) passes the AAOIFI interest-bearing debt screen. The debt screen caps Riba-based borrowing, meaning conventional bank loans, bonds and similar financing, at 30% of market capitalisation, limiting a shareholder's exposure to interest-based leverage. Protalix Biotherapeutics, Inc. is inside that limit in the latest screening. Because market capitalisation changes daily, a company's debt ratio can drift toward or away from the limit even without new borrowing, which is why this screen is reassessed every month.

What is the dividend purification factor for Protalix Biotherapeutics, Inc. PLX stock?

As of September 2026, the dividend purification factor for Protalix Biotherapeutics, Inc. (PLX) is 99.45%. Purification (Tazkiyah) is the practice of donating to charity the portion of dividend income attributable to incidental non-permissible sources, typically interest earned on a company's cash, and AAOIFI methodology requires it even for fully compliant stocks. The purification factor is the figure Halal investors use to work out that donation on Protalix Biotherapeutics, Inc. dividends. It is recalculated with each monthly screening as new financial data arrives, and the Tabadulat app can help you calculate and track purification across your whole portfolio.

Does Protalix Biotherapeutics, Inc. PLX pass the AAOIFI Preference Share screen?

Yes, as of September 2026, Protalix Biotherapeutics, Inc. stock (PLX) passes the AAOIFI preference share screen. AAOIFI Shariah Standard No. 21 prohibits investing in preference shares because they grant holders guaranteed or priority rights to dividends and capital ahead of ordinary shareholders, a structure that conflicts with the Shariah principle that investors should share profit and loss in proportion to their ownership. Protalix Biotherapeutics, Inc. has no impermissible preference share structure affecting its ordinary shares, so the stock is compliant on this criterion. Like all AAOIFI screens, this is verified in each monthly review.

Invest Halal, Anytime, Anywhere

Download the Tabadulat app and start building your Shariah-compliant portfolio in minutes.

English

العربية

Is Protalix Biotherapeutics (PLX) stock Halal?

NYSE

Shariah-Compliant

Not Shariah

Under AAOIFI Shariah Standard No. 21, a Halal stock keeps non-permissible income below 5% of revenue and interest-bearing debt and investments each below 30% of market capitalisation. Protalix Biotherapeutics, Inc. (PLX) passes all four screens as of September 2026, with a dividend purification factor of 99.45%.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

213

Website:

https://www.protalix.com

Market cap:

$209M

P/E ratio:

11.3

Dividend yield:

52-week range:

$1.52 - $3.19

Data as of:

3 September 2026

Screening history:

September 2026: PASS

Protalix Biotherapeutics is a biopharmaceutical company focused on developing and manufacturing therapeutic proteins using its proprietary plant cell-based expression system. This innovative platform allows for the production of recombinant proteins, offering advantages such as scalability and cost-effectiveness compared to traditional mammalian cell culture methods. Protalix is prominently engaged in advancing solutions within the rare diseases sector, exemplifying its commitment to addressing unmet medical needs. One of its leading products targets Gaucher disease, a hereditary enzyme deficiency disorder. For Muslim investors, though, the most pressing question is simpler: is Protalix Biotherapeutics a Halal investment?

Is Protalix Biotherapeutics Shariah compliant?

Technology companies rarely fail AAOIFI screening on what they sell. Software, hardware and digital services are permissible business activities, so for a company like Protalix Biotherapeutics the Shariah question moves to the balance sheet: how much of its market value sits in interest bearing debt, how much of its cash earns Riba in conventional deposits, and whether incidental income from impermissible sources creeps past 5% of revenue. These are exactly the ratios AAOIFI Shariah Standard No. 21 polices, and they move every month with the share price.

Does Protalix Biotherapeutics pass the business activity test?

Yes. In the September 2026 screening Protalix Biotherapeutics holds an overall PASS, which a stock only earns when its core business clears the activity screen. The watch item for technology names is incidental: cash returns and platform content can carry impermissible elements, which AAOIFI tolerates only below the thresholds.

Is Protalix Biotherapeutics' income Halal?

Yes, within AAOIFI's tolerance. Protalix Biotherapeutics' income from non-permissible sources stays below 5% of revenue in the September 2026 screening, and the small impure portion is handled through purification: the factor of 99.45% tells holders of PLX what share of each dividend to keep and what remainder to donate to charity.

Does Protalix Biotherapeutics meet AAOIFI's debt and investment ratio requirements?

Yes. Both caps hold this month: interest bearing investments and interest bearing debt each stay below 30% of market capitalisation. Because the caps move with the share price, our Shariah Supervisory Board has PLX re-screened every month, and the result above always shows the latest verdict.

Tabadulat is an ADGM regulated brokerage whose license covers Shari'a Compliant Regulated Activities, as the FSRA permission names them. New to the terminology? Gharar and Maysir, Sukuk, Zakat and purification are all explained in plain English.

New to the four screens? Read Why a Halal Stock Screener Matters for Halal Investing

Frequently asked questions

Related stocks

Mobile login screen for Tabadulat with fields to enter email, a Continue button, an option to create an account, and a language selector showing EN.

Step 1

Open your account.

Create your Tabadulat account in minutes: enter your details, complete identity verification, and add funds by secure transfer in multiple currencies. You're ready to start investing in Halal stocks the same day.

Mobile screen showing add money interface with 100 AED amount and Manual Bank Transfer payment method selected, noting 1-2 business days processing.

Step 2

Deposit.

Add funds to your account using a secure payment method. You can deposit in multiple currencies to get started.

Step 3

Screen.

Screen Stocks for Free and explore a wide range of stocks that are ethically screened for Shariah compliance. Use our Halal Stock Screener to find the best opportunities.